XTL BIOPHARMACEUTICALS LTD - SPONSORED ADR NE (XTLB)
Historical Holders from Q1 2017 to Q4 2025
-
Type / Class
-
Equity / SPONSORED ADR NE
-
Symbol
-
XTLB on Nasdaq
-
Price per share
-
$0.5800
-
All holders as of 30 Sep 2025
-
Q3 2025
-
Total 13F shares as of 30 Sep 2025
-
226,923
-
Holdings value
-
$265,800
-
% of all portfolios
-
0%
-
Share change
-
-1,573
-
Value change
-
-$1,841
-
Average sells %
-
0%
-
Number of holders
-
4
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
As of 30 Sep 2025, XTL BIOPHARMACEUTICALS LTD - SPONSORED ADR NE (XTLB) has 4 institutional shareholders filing 13F forms.
They hold 226,923 shares
.
Institutional Holders of XTL BIOPHARMACEUTICALS LTD - SPONSORED ADR NE (XTLB) across Reporting Periods
| Period |
Reported Shares, Excl. Options |
Value, Excl. Options |
Value Change |
Puts Notional Value |
Calls Notional Value |
Price |
Investors |
|
2025 Q4
|
12,887 |
$7,474 |
+$7,474 |
|
|
$0.5800 |
1 |
|
2025 Q3
|
226,923 |
$265,800 |
-$1,841 |
|
|
$1.17 |
4 |
|
2025 Q2
|
228,496 |
$261,097 |
-$24,978 |
|
|
$1.14 |
4 |
|
2025 Q1
|
248,304 |
$298,679 |
+$25,167 |
|
|
$1.22 |
4 |
|
2024 Q4
|
228,193 |
$462,739 |
-$7,273 |
|
|
$2.03 |
3 |
|
2024 Q3
|
231,858 |
$556,386 |
-$50,432 |
|
|
$2.40 |
3 |
|
2024 Q2
|
253,058 |
$613,370 |
-$16,662 |
|
|
$2.40 |
4 |
|
2024 Q1
|
258,944 |
$727,758 |
+$57,489 |
|
|
$2.81 |
5 |
|
2023 Q4
|
239,213 |
$241,734 |
+$136 |
|
|
$1.01 |
5 |
|
2023 Q3
|
239,879 |
$215,794 |
-$431 |
|
|
$0.8988 |
4 |
|
2023 Q2
|
240,259 |
$240,367 |
-$600 |
|
|
$1.00 |
3 |
|
2023 Q1
|
240,659 |
$315,720 |
-$1,935 |
|
|
$1.31 |
2 |
|
2022 Q4
|
242,159 |
$293,358 |
-$2,420 |
|
|
$1.21 |
3 |
|
2022 Q3
|
443,047 |
$492,000 |
-$3,866 |
|
|
$1.11 |
3 |
|
2022 Q2
|
446,547 |
$678,000 |
-$2,759 |
|
|
$1.52 |
3 |
|
2022 Q1
|
447,859 |
$1,046,000 |
-$65,725 |
|
|
$2.37 |
4 |
|
2021 Q4
|
472,127 |
$1,307,000 |
-$67,908 |
|
|
$2.77 |
4 |
|
2021 Q3
|
487,426 |
$2,135,000 |
-$54,036 |
|
|
$4.38 |
6 |
|
2021 Q2
|
500,698 |
$1,999,000 |
-$29,157 |
|
|
$3.99 |
5 |
|
2021 Q1
|
508,501 |
$1,693,000 |
+$114,744 |
|
|
$3.33 |
6 |
|
2020 Q4
|
474,130 |
$1,437,000 |
+$85,428 |
|
|
$3.03 |
4 |
|
2020 Q3
|
446,243 |
$848,000 |
+$12,626 |
|
|
$1.90 |
4 |
|
2020 Q2
|
439,607 |
$699,000 |
+$3,043 |
|
|
$1.59 |
3 |
|
2020 Q1
|
437,707 |
$515,000 |
+$3,649 |
|
|
$1.18 |
3 |
|
2019 Q4
|
434,607 |
$594,000 |
-$60,051 |
|
|
$1.37 |
3 |
|
2019 Q3
|
481,451 |
$687,000 |
+$25,831 |
|
|
$1.43 |
6 |
|
2019 Q2
|
463,299 |
$927,000 |
-$2,958 |
|
|
$2.00 |
5 |
|
2019 Q1
|
464,799 |
$1,096,000 |
+$964 |
|
|
$2.36 |
5 |
|
2018 Q4
|
464,842 |
$804,000 |
-$65,735 |
|
|
$1.73 |
6 |
|
2018 Q3
|
97,539 |
$208,000 |
-$10,838 |
|
|
$2.20 |
4 |
|
2018 Q2
|
104,113 |
$193,000 |
+$113,891 |
|
|
$1.85 |
4 |
|
2018 Q1
|
43,951 |
$76,000 |
+$11,436 |
|
|
$1.75 |
4 |
|
2017 Q4
|
36,722 |
$84,000 |
-$23,281 |
|
|
$2.30 |
2 |
|
2017 Q3
|
49,712 |
$118,000 |
+$2,452 |
|
|
$2.36 |
4 |
|
2017 Q2
|
48,930 |
$155,000 |
+$38,506 |
|
|
$3.16 |
3 |
|
2017 Q1
|
36,841 |
$97,000 |
+$97,000 |
|
|
$2.63 |
3 |